CYTK Cytokinetics Inc

$65.44

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Cytokinetics Inc

Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.

Website: https://www.cytokinetics.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1061983
Address
280 EAST GRAND AVENUE, ., SOUTH SAN FRANCISCO, CA, US
Valuation
Market Cap
$4.71B
P/E Ratio
nan
PEG Ratio
-0.42
Price to Book
60.31
Performance
EPS
$-5.26
Dividend Yield
—
Profit Margin
0.00%
ROE
-572.00%
Technicals
50D MA
$42.94
200D MA
$50.45
52W High
$68.76
52W Low
$32.74
Fundamentals
Shares Outstanding
119M
Target Price
$78.30
Beta
0.94

CYTK EPS Estimates vs Actual

● Estimated
● Actual

CYTK News & Sentiment

Nov 20, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
Nov 19, 2025 • Benzinga NEUTRAL
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. ( NASDAQ: CYTK ) ; Fortrea Holdings, Inc. ( NASDAQ: FTRE ) ; Ibotta, Inc. ( NYSE: IBTA ) ; and Stride, Inc. ( NYSE: LRN ) : Grabar Law Office is Investigating Claims on Your Behalf - Fortrea Holdings ( NASDAQ:FTRE ) , Cytokinetics ( NASDAQ:CYTK )
PHILADELPHIA, Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. ( NASDAQ:CYTK ) . The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
Nov 18, 2025 • Benzinga NEUTRAL
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. ( NASDAQ: CYTK ) ; enCore Energy Corp. ( NASDAQ: EU ) ; Fluor Corporation ( NYSE: FLR ) ; Fortrea Holdings, Inc. ( NASDAQ: FTRE ) ; and Ibotta, Inc. ( NYSE: IBTA ) : Grabar Law Office is Investigating Claims on Your Behalf - enCore Energy ( NASDAQ:EU ) , Cytokinetics ( NASDAQ:CYTK )
PHILADELPHIA, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. ( NASDAQ:CYTK ) . The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
Nov 17, 2025 • Benzinga NEUTRAL
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK - Cytokinetics ( NASDAQ:CYTK )
NEW YORK, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ( "Cytokinetics" or the "Company" ) ( NASDAQ:CYTK ) of a class action securities lawsuit.
Nov 17, 2025 • Benzinga NEUTRAL
DEADLINE ALERT for CYTK: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Cytokinetics ( NASDAQ:CYTK )
LOS ANGELES, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Nov 17, 2025 • Zacks Commentary NEUTRAL
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
Sentiment Snapshot

Average Sentiment Score:

0.046
50 articles with scored sentiment

Overall Sentiment:

Neutral

CYTK Reported Earnings

Aug 07, 2025
Jun 30, 2025 (Pre market)
0.3 Surprise
  • Reported EPS: $-1.12
  • Estimate: $-1.42
  • Whisper: —
  • Surprise %: 21.1%
May 06, 2025
Mar 31, 2025 (Post market)
0.0 Surprise
  • Reported EPS: $-1.36
  • Estimate: $-1.36
  • Whisper: —
  • Surprise %: 0.2%
Feb 27, 2025
Dec 31, 2024 (Post market)
-0.09 Surprise
  • Reported EPS: $-1.26
  • Estimate: $-1.17
  • Whisper: —
  • Surprise %: -7.3%
Nov 06, 2024
Sep 30, 2024 (Post market)
-0.11 Surprise
  • Reported EPS: $-1.36
  • Estimate: $-1.25
  • Whisper: —
  • Surprise %: -8.8%
Aug 08, 2024
Jun 30, 2024 (Post market)
-0.25 Surprise
  • Reported EPS: $-1.31
  • Estimate: $-1.06
  • Whisper: —
  • Surprise %: -23.6%
May 08, 2024
Mar 31, 2024 (Post market)
-0.19 Surprise
  • Reported EPS: $-1.33
  • Estimate: $-1.14
  • Whisper: —
  • Surprise %: -16.7%
Feb 27, 2024
Dec 31, 2023 (Post market)
-0.41 Surprise
  • Reported EPS: $-1.38
  • Estimate: $-0.97
  • Whisper: —
  • Surprise %: -42.3%
Nov 02, 2023
Sep 30, 2023 (Post market)
-0.61 Surprise
  • Reported EPS: $-1.35
  • Estimate: $-0.74
  • Whisper: —
  • Surprise %: -82.4%
Aug 03, 2023
Jun 30, 2023 (Post market)
-0.19 Surprise
  • Reported EPS: $-1.34
  • Estimate: $-1.15
  • Whisper: —
  • Surprise %: -16.5%

Financials